Rights and permissions
About this article
Cite this article
Adalimumab more cost effective than infliximab in early RA. Pharmacoecon. Outcomes News 483, 3–4 (2005). https://doi.org/10.2165/00151234-200504830-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504830-00004